Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389124 | 1.00 | TRPV1 (1.00) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL138342 | 1.00 | TRPV1 (1.00) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL4262912 | 0.88 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL4265025 | 0.81 | TRPV1 (0.78) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL14422335 | 0.79 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL4262793 | 0.78 | TRPV1 (0.82) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL3712104 | 0.77 | TRPV1 (0.80) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL4269392 | 0.77 | TRPV1 (0.73) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL16690819 | 0.77 | TRPV1 (0.66) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL3095680 | 0.76 | HSD11B1 (0.76) | TRPV1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | claimed |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | claimed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | claimed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | claimed |
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4568658-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119947711-A | Organogels for sustained drug delivery, methods of preparation and uses thereof | 视尔普斯眼科公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250140406-A1 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | INSIGHT MOLECULAR DIAGNOSTICS INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | disclosed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024035690-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023148231-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis SA (CH) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-114533816-B | Medicament for treating chronic cough and pharmaceutical composition, preparation method and application thereof | 广州医科大学附属第一医院（广州呼吸中心） | 2022-11-22 | — | — | CN | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114533816-A | Medicament for treating chronic cough and pharmaceutical composition, preparation method and application thereof | 广州医科大学附属第一医院（广州呼吸中心） | 2022-05-27 | — | — | CN | disclosed |
| US-11339122-B2 | hTRPV1 chemical agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | KIT, IL33, LY96 | TRPV1 2697/4885GAA 1036/4885NPSR1 3537/4885 |
| US-11339122-B2 | hTRPV1 chemical agents | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885GAA 4709/4885NPSR1 322/4885 |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | CNR2, TRPV1, CNR1 | TRPV1 2/4885GAA 2771/4885NPSR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.